New study tracks Alhemo's Real-World safety in hemophilia patients

NCT ID NCT06831734

NEW ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 16, 2026 · Last updated Jun 16, 2026

Summary

This study monitors the long-term safety and effectiveness of the drug Alhemo in 30 people with hemophilia A or B who do not have inhibitors. Participants are treated in routine clinical practice in Japan and observed for about 2 years each. The goal is to track side effects and serious events to ensure the drug works safely outside of controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A, HAEMOPHILIA B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Arin Clinic Shonika_Pediatrics

    Okinawa, 901-2132, Japan

  • Chiba university hospital_Pediatrics

    Chiba, 260-8677, Japan

  • Fukaya Red Cross Hospital_Haematology

    Saitama, 366-0052, Japan

  • Hamamatsu Medical Center_Pediatrics

    Shizuoka, 432-8580, Japan

  • Hoshi General Hospital_Pediatrics

    Fukushima, 963-8501, Japan

  • Hyogo Prefectural Amagasaki General Medical Center_Haematology

    Hyōgo, 660-8550, Japan

  • Ishiyama Clinic

    Yamagata, 992-0035, Japan

  • Iwata City Hospital_Haematology

    Shizuoka, 438-8550, Japan

  • Kansai Medical University Hospital_Pediatrics

    Osaka, 573-1191, Japan

  • Matsue red cross hospital_Pediatrics

    Shimane, 690-8506, Japan

  • Miyagi Children's Hospital_Hematology-Oncology

    Miyagi, 989-3126, Japan

  • Nagano Children's Hospital_Hematology-Oncology

    Nagano, 399-8288, Japan

  • Nagano red cross hospital_Pediatrics

    Nahano, 380-8582, Japan

  • Nanbu Medical Center & Children's Medical Center_Pediatric Hematology

    Okinawa, 901-1193, Japan

  • National Center for Child Health and Development_Hematology

    Tokyo, 157-8535, Japan

  • National Hospital Organization Awara Hospital_Hematology and Oncology

    Fukui, 910-4272, Japan

  • Ogikubo Hospital_Blood Coagulation

    Tokyo, 167-0035, Japan

  • Saitama Children's Med Centre_Hematology-Oncology

    Saitama, 330-8777, Japan

  • Saitama Medical Univ. Hospital Saitama medical center_Department of Transfusion Medicine and Cell Therapy

    Kawagoe, Japan

  • Saitama Medical Univ. Hospital Saitama medical center_Department of Transfusion Medicine and Cell Therapy

    Saitama, 350-8550, Japan

  • St. Marianna Univ., Yokohama City Seibu HP, Pediatrics Dept,

    Yokohama-shi, Kanagawa, 241-0811, Japan

  • St. Marianna University School of Medicine Hospital_Pediatrics

    Kanagawa, 216-8511, Japan

  • University of the Ryukyus Hospital_Endocrinology and Metabolism, Hematology and Rheumatology

    Okinawa, 901-2725, Japan

Conditions

Explore the condition pages connected to this study.